Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
Primary Industries
- Drugs
- Disease
- Therapeutic
- Pharmaceuticals
- Biotechnology
- Pain
- Cancer
- Central Nervous System
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 6588
License Grant
Licensor hereby grants to Licensee an exclusive, with right to sublicense, license or sublicense, as applicable, under the Infinity Know-How and Infinity Patent Rights to Commercialize FAAH Products in the Territory.
License Property
FAAH shall mean Fatty Acid Amide Hydrolase (also known as FAAH-1) or FAAH-2.
The Parties are interested in forming an alliance whose goal is to develop and commercialize FAAH Products in the United States.
The Company has commenced clinical development of its internally discovered drug candidate, IPI-940, a novel inhibitor of the enzyme fatty acid amide hydrolase, or FAAH. After Phase 1 investigation, select Licensees will have the right to assume worldwide development and commercialization activities under the Licensor's FAAH program.
IPI-940, a potential treatment for a broad range of neuropathic and inflammatory pain conditions, is a selective, orally available inhibitor of FAAH. Inhibitors of FAAH have the ability to potentiate the magnitude and duration of the body’s endogenous analgesic agents through their effects on the endocannabinoid system. After Phase 1 investigation, the Licensees will have the right to assume worldwide development and commercialization activities under the FAAH program.
IPSCIO Record ID: 4255
License Grant
Licensor hereby grants to Licensee during the Term an exclusive, sublicenseable license or sublicense, as applicable, under the Infinity Know-How and Infinity Patent Rights to Commercialize FAAH Products in the Territory.
License Property
FAAH shall mean Fatty Acid Amide Hydrolase (also known as FAAH-1) or FAAH-2.
An innovative drug discovery and development company, today announced that it has commenced clinical development of its fourth internally discovered drug candidate, IPI-940, a novel inhibitor of the enzyme fatty acid amide hydrolase, or FAAH. After Phase 1 investigation, two Licensees will have the right to assume worldwide development and commercialization activities under the Licensor's FAAH program.
Field of Use
IPI-940, a potential treatment for a broad range of neuropathic and inflammatory pain conditions, is a selective, orally available inhibitor of FAAH. Inhibitors of FAAH have the ability to potentiate the magnitude and duration of the body’s endogenous analgesic agents through their effects on the endocannabinoid system. After Phase 1 investigation, the Licensees will have the right to assume worldwide development and commercialization activities under the FAAH program.
IPSCIO Record ID: 4251
License Grant
Licensor hereby grants to Licensee of Bermuda during the Term an exclusive, sublicenseable license or sublicense, as applicable, under the Infinity Know-How, Infinity Patent Rights and Product Trademarks to Commercialize Products in the applicable Territory.
License Property
Alliance Product shall mean (a) products and product candidates that Interact with the Hedgehog Pathway, (b) products and product candidates that Interact with FAAH, and (c) products and product candidates that arise out of the Discovery Projects and either (x) have been separately identified in the Research Plan submitted by Infinity to Licensee as of October 1 immediately prior to the end of the Funded Discovery Period, or (y) have achieved Development Candidate status on or before the end of the Funded Discovery Period; provided, however, that, Alliance Products will not include (i) products and product candidates that Interact with Hsp90 or Bcl-2/Bcl-xL, (ii) any products and product candidates that Infinity in-licenses or otherwise acquires rights to from a Third Party after the Effective Date, and (iii) any Opt-Out Products, Assumed Products or Related Products associated therewith.
FAAH shall mean Fatty Acid Amide Hydrolase (also known as FAAH-1) or FAAH-2.
Hedgehog Pathway shall mean all of the following members of the Hedgehog cell-signaling pathway (i) all hedgehog ligands (Sonic, Indian, Desert) and transmembrane transport-like proteins, like Disp1 or Disp2, involved in the secretion of the HH ligand, (ii) Smoothened (Smo), including alternatively spliced forms and Smo with activating mutations, (iii) all Gli transcription factors (Gli 1, 2, 3), (iv) mutated or unmutated Patched (Ptch) receptor 1 and 2, (v) Cdo, Cdon and Boc (brother of Cdo), (vi) Suppressor of Fused (SuFu), (vii) Cdc2l1 kinase, (viii) Hedgehog interacting protein (HHIP), and (ix) ARL13B.
Field of Use
The Parties are interested in forming an alliance whose goal is to (a) enable Infinity to build a portfolio of oncology products and a commercial oncology organization in the United States and (b) provide Licensee with a pipeline of products to commercialize outside of the United States.
IPSCIO Record ID: 6903
License Grant
Licensor of Bermuda hereby grants to Licensee during the Term an exclusive, sublicenseable license or sublicense, as applicable, under the Infinity Know-How, Infinity Patent Rights and Product Trademarks to Commercialize Products in the applicable Territory.
License Property
Alliance Product shall mean (a) products and product candidates that Interact with the Hedgehog Pathway, (b) products and product candidates that Interact with FAAH, and (c) products and product candidates that arise out of the Discovery Projects and either (x) have been separately identified in the Research Plan submitted by Infinity to MICL as of October 1 immediately prior to the end of the Funded Discovery Period, or (y) have achieved Development Candidate status on or before the end of the Funded Discovery Period; provided, however, that, Alliance Products will not include (i) products and product candidates that Interact with Hsp90 or Bcl-2/Bcl-xL, (ii) any products and product candidates that Infinity in-licenses or otherwise acquires rights to from a Third Party after the Effective Date, and (iii) any Opt-Out Products, Assumed Products or Related Products associated therewith.
FAAH shall mean Fatty Acid Amide Hydrolase (also known as FAAH-1) or FAAH-2.
Hedgehog Pathway shall mean all of the following members of the Hedgehog cell-signaling pathway (i) all hedgehog ligands (Sonic, Indian, Desert) and transmembrane transport-like proteins, like Disp1 or Disp2, involved in the secretion of the HH ligand, (ii) Smoothened (Smo), including alternatively spliced forms and Smo with activating mutations, (iii) all Gli transcription factors (Gli 1, 2, 3), (iv) mutated or unmutated Patched (Ptch) receptor 1 and 2, (v) Cdo, Cdon and Boc (brother of Cdo), (vi) Suppressor of Fused (SuFu), (vii) Cdc2l1 kinase, (viii) Hedgehog interacting protein (HHIP), and (ix) ARL13B.
Field of Use
Licensee and Licensor are interested in forming an alliance whose goal is to (a) enable Infinity to build a portfolio of oncology products and a commercial oncology organization in the United States and (b) provide Licensor with a pipeline of products to commercialize outside of the United States.
IPSCIO Record ID: 4330
License Grant
The Licensor, on behalf of itself and its Affiliates, grants to the Licensee during the Term an exclusive, sublicenseable, irrevocable license or sublicense, as applicable, under the Know-How and Patent Rights to Develop, Manufacture and Commercialize FAAH Products anywhere in the world.
License Property
The Licensor transfers and assigns to the Licensee all right, title and interest in and to any product name or related trademark that had been selected by the Licensor or its Affiliates with respect to the FAAH Products and any Internet domain names incorporating any Product Trademark or any variation or part of any such Product Trademark as its URL address.
FAAH shall mean Fatty Acid Amide Hydrolase
Fatty acid amide hydrolase, (FAAH, Oleamide hydrolase, Anandamide amidohydrolase), is an integral membrane protein that hydrolyzes bioactive amides, including anandamide, to free fatty acid and ethanolamine. In humans, FAAH is mainly present in the pancreas, brain, kidney, skeletal muscle, and placenta.
IPSCIO Record ID: 303746
License Grant
The parties entered into an exclusive worldwide license agreement to develop and commercialize V158866, a novel oral, selective fatty acid amide hydrolase inhibitor that was discovered using the Vernalis Design Platform.
License Property
V158866 is for post-traumatic stress disorder and other central nervous system diseases. V158866 is a novel oral, selective fatty acid amide hydrolase inhibitor that was discovered using the Vernalis Design Platform.
Licensor is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines.
Field of Use
Licensee will utilize the inhibitor, V158866, for post-traumatic stress disorder and other central nervous system diseases.
Licensee is a biopharmaceutical company committed to developing treatments for psychiatric disorders.
IPSCIO Record ID: 5599
License Grant
The agreement granted a non-exclusive license and sublicense to use the oral formulations of these two product candidates and granted a non-exclusive license to use its controlled release technologies.
License Property
Bicifadine is a serotonin-norepinephrine reuptake inhibitor (SNRI). It has been developed as an analgesic and is currently under development for the treatment of various pain conditions. Phase III trials were completed in 2006 for treating chronic low back pain, and the drug is currently being tested to assess its efficacy in treating pain associated with osteoarthritis, acute post-surgical pain, neuropathic pain and pain associated with dental surgery. Its usefulness in surgical or dental pain is dubious, however, as most monoamine uptake-inhibiting antidepressants have little effect in treating acute pain–they are far more effective in cases of chronic, neuropathic pain.
Field of Use
The newly formed Licensee develops controlled release formulations of bicifadine for the treatment of pain and ocinaplon for the treatment of anxiety disorders and epilepsy.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
